Document Detail

The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer.
MedLine Citation:
PMID:  23341367     Owner:  NLM     Status:  Publisher    
In 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer.
Thierry Conroy; Céline Gavoille; Emmanuelle Samalin; Marc Ychou; Michel Ducreux
Related Documents :
18220507 - Natural and synthetic iminosugars as carbohydrate processing enzyme inhibitors for canc...
8462127 - Glutathione depletion increases the cytotoxicity of melphalan to pc-3, an androgen-inse...
17442577 - Antimicrobial and cytotoxic activity of agelasine and agelasimine analogs.
17889047 - Furoquinoline alkaloids of ertela (monnieria) trifolia (l.) kuntze from the suriname ra...
19771277 - The synergism between belotecan and cisplatin in gastric cancer.
24140887 - Luteolin attenuates tgf-β1-induced epithelial-mesenchymal transition of lung cancer ce...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-23
Journal Detail:
Title:  Current oncology reports     Volume:  -     ISSN:  1534-6269     ISO Abbreviation:  Curr Oncol Rep     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888967     Medline TA:  Curr Oncol Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
EA 4360 and Department of Medical Oncology, Centre Alexis Vautrin, Université de Lorraine, CS 30519, 54519, Vandoeuvre-lès-Nancy Cedex, France,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Swedish national public health policy report 2010.
Next Document:  Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Application...